Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT03814148

Efficacy and Safety of Leningrado 5 Association in the Treatment of Hypertension

Randomized, Double-blind, Double-dummy, National, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Leningrado 5 Association in the Treatment of Hypertension

Status
Withdrawn
Phase
Phase 3
Study type
Interventional
Enrollment
0 (actual)
Sponsor
EMS · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to evaluate the efficacy and safety of Leningrado 5 association on the treatment of hypertension.

Conditions

Interventions

TypeNameDescription
DRUGLENINGRADO 5 association1 coated sustained-release tablet, oral, once a day.
DRUGNatrilix® SR1 coated sustained-release tablet, oral, once a day.
OTHERNatrilix SR Placebo1 coated sustained-release tablet, oral, once a day.
OTHERLeningrado 5 association Placebo1 coated sustained-release tablet, oral, once a day.

Timeline

Start date
2019-06-01
Primary completion
2020-06-01
Completion
2020-09-01
First posted
2019-01-23
Last updated
2021-02-24

Source: ClinicalTrials.gov record NCT03814148. Inclusion in this directory is not an endorsement.